La mutation BRAF dans le carcinome papillaire de la thyroïde : intérêt dans le pronostic à long terme et dans l’iodosensibilité

A. Zoghlami1, F. Roussel2, J.-C. Sabourin2, J.-M. Kuhn3, J.-P. Marie1, D. Dehesdin1, O. Choussy1
1Service d’ORL et de chirurgie cervico-faciale, hôpital Charles-Nicolle, CHU, 1, rue de Germont, 76031 Rouen cedex, France
2Service d’anatomo-pathologie, hôpital Charles-Nicolle, CHU, 1, rue de Germont, 76031 Rouen cedex, France
3Service d’endocrinologie, hôpital Charles-Nicolle, CHU, 1, rue de Germont, 76031 Rouen cedex, France

Tài liệu tham khảo

Leenhardt, 2011, Epidemiology of thyroid carcinoma over the world, Ann Endocrinol (Paris), 72, 136, 10.1016/j.ando.2011.03.025 Xing, 2005, BRAF mutation in thyroid cancer, Endocr Relat Cancer, 12, 245, 10.1677/erc.1.0978 Albores-Saavedra, 2007, Changing patterns in the incidence and survival of thyroid cancer with follicular phenotype-papillary, follicular, and anaplastic: a morphological and epidemiological study, Endocr Pathol, 18, 1, 10.1007/s12022-007-0002-z Mazzaferri, 1994, Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer, Am J Med, 97, 418, 10.1016/0002-9343(94)90321-2 Mazzaferri, 2001, Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer, J Clin Endocrinol Metab, 86, 1447, 10.1210/jcem.86.4.7407 Ito, 2007, Risk factors contributing to a poor prognosis of papillary thyroid carcinoma: validity of UICC/AJCC TNM classification and stage grouping, World J Surg, 31, 838, 10.1007/s00268-006-0455-0 Döbert, 2004, Differentiated thyroid carcinoma: the new UICC 6th edition TNM classification system in a retrospective analysis of 169 patients, Thyroid, 14, 65, 10.1089/105072504322783867 Trovisco, 2005, Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients’ age but not with tumour aggressiveness, Virchows Arch, 446, 589, 10.1007/s00428-005-1236-0 Nikiforova, 2003, BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas, J Clin Endocrinol Metab, 88, 5399, 10.1210/jc.2003-030838 Lupi, 2007, Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma, J Clin Endocrinol Metab, 92, 4085, 10.1210/jc.2007-1179 Xing, 2005, BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer, J Clin Endocrinol Metab, 90, 6373, 10.1210/jc.2005-0987 Fugazzola, 2004, BRAF mutations in an Italian cohort of thyroid cancers, Clin Endocrinol (Oxf), 61, 239, 10.1111/j.1365-2265.2004.02089.x Ito, 2009, BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients, Endocr J, 56, 89, 10.1507/endocrj.K08E-208 Lee, 2007, Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis, Cancer, 110, 38, 10.1002/cncr.22754 Kim, 2012, The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis, Cancer, 118, 1764, 10.1002/cncr.26500 Girelli, 1999, Differentiated thyroid carcinoma (DTC) in the elderly: disease outcome, therapeutic approach, and long-term results in a group of 314 patients, J Endocrinol Invest, 22, 45 Ugolini, 2007, Presence of BRAF V600E in very early stages of papillary thyroid carcinoma, Thyroid, 17, 381, 10.1089/thy.2006.0305 Sedliarou, 2004, The BRAFT1796A transversion is a prevalent mutational event in human thyroid microcarcinoma, Int J Oncol, 25, 1729 Elisei, 2008, BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study, J Clin Endocrinol Metab, 93, 3943, 10.1210/jc.2008-0607 Cañadas Garre, 2011, BRAF(T1799A) mutation in the primary tumor as a marker of risk, recurrence, or persistence of papillary thyroid carcinoma, Endocrinol Nutr, 58, 175, 10.1016/j.endonu.2011.02.006 O’Neill, 2010, BRAF(V600E) mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer, Surgery, 148, 1139, 10.1016/j.surg.2010.09.005 Riesco-Eizaguirre, 2006, The oncogene BRAF V600E is associated with a high-risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane, Endocr Relat Cancer, 13, 257, 10.1677/erc.1.01119 Durante, 2007, BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism, J Clin Endocrinol Metab, 92, 2840, 10.1210/jc.2006-2707 Oler, 2009, High prevalence of BRAF mutation in a Brazilian cohort of patients with sporadic papillary thyroid carcinomas: correlation with more aggressive phenotype and decreased expression of iodide-metabolizing genes, Cancer, 115, 972, 10.1002/cncr.24118 Mian, 2008, Molecular characteristics in papillary thyroid cancers (PTCs) with no 131I uptake, Clin Endocrinol (Oxf), 68, 108, 10.1111/j.1365-2265.2007.03008.x